| International Isotopes, Inc. | |||
| Ticker: | INIS | 2600 Longhorn Boulevard, Suite 105 | |
| Exchange: | NASDAQ-Small Cap Market | Austin, TX 78758 | |
| Industry: | Manufacturing (SIC Code 2835) | (512) 834-1822 | |
| Type of Shares: | Common Shares | Filing Date: | 5/1/97 | |
| U.S. Shares: | 2,200,000 | Offer Date: | 8/13/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 2,200,000 | Offer Price: | $9.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.72 | |
| Offering Amount: | $19,800,000 | Selling: | $0.36 | |
| Expenses: | - | Reallowance: | $0.05 | |
| Shares Out After: | 6,086,446 |
| Manager | Tier | Phone |
| Keane Securities Co., Inc. | Lead Manager | (212) 422-7941 |
| Issuer's Law Firm: | Epstein Becker & Green |
| Bank's Law Firm: | Orrick, Herrington & Sutcliffe |
| Auditor: | KPMG Peat Marwick |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $0.78 | Assets: | $4.26 | ||
| Net Income: | -$0.83 | Curr Assets: | |||
| EPS: | -$0.22 | Liabilities: | $2.70 | ||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$1.42 | Equity: | $1.56 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a development stage company which intends to be the first independent domestic producer of pharmaceutical grade isotopes and radiopharmaceuticals for commercial sale to the nuclear medicine industry. Radioisotopes, which are indispensable components of nuclear medicine, are radiation emitting atoms that are used for both medical diagnostics and in-the-body therapeutics. The company also intends, under an exclusive worldwide license, to complete development of and to manufacture and market a high resolution medical imaging camera, key components of which are patented, for use in nuclear diagnostic medicine, which the cmpany believes will have resolution at least four times greater than any imaging camera currently on the market. When a specifically selected radioisotope is attached or "tagged" to one of a variety of pharmaceuticals, the resulting product is known as a radiopharmaceutical. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay certain indebtedness; to reconfigure, assemble, test and commence operation of the LINAC, including capital expenditures to procure radioisotope processing equipment; to acquire radioisotopes for distribution prior to full operation of the LINAC; to complete development of, manufacture and market a proposed pulsed plasma device; and for working capital and general corporate purposes. |